Drugs / Olatorepatide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07685808 | Jul 2026 → Jan 2028 expected | obesity disorder | Regeneron Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07431086 | Mar → Nov 2026 expected | obesity disorder | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-09 | Regeneron Pharmaceuticals | Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients regeneron.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olatorepatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07685808 ↗ |
| Known as | Olatorepatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068153 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068153 ↗ |